Article
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.
CNS oncology - 1 Nov 2019
Makhlin Igor, Salinas Ryan D, Zhang Daniel, Jacob Fadi, Ming Gou-Li, Song Hongjun, Saxena Deeksha, Dorsey Jay F, Nasrallah MacLean P, Morrissette Jennifer Jd, Binder Zev A, O'Rourke Donald M, Desai Arati S, Brem Steven, Bagley Stephen J
Abstract excerpt
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis. The EGFR gene is among the most commonly deranged genes in GBM and thus an important therapeutic target. We report the case of a young female with heavily pretreated EGFR-mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.